Lundbeck posts solid operational performance though sales decline

11 November 2021

Danish CNS specialist Lundbeck (LUND: CO) has reported financial results, showing that revenue reached 12,246 million Danish kroner ($1,902 million) in the first nine months of 2021, a decline of 5% in local currencies primarily due to loss of exclusivity erosion on Northera (droxidopa).

Earnings before interest and taxes (EBIT) grew 29% compared to the same period in 2020 and reached 2,004 million kroner. EBIT margin reached 16.4%. EPS grew by 28% for the period, reaching DKK 6.64.

In aggregate, strategic brands grew 17% in local currencies reaching 6,815 million kroner in the first nine months, representing 56% of total revenue. In the third quarter of 2021, all strategic brands have continued their double-digit growth. Based on trends in Trintellix (vortioxetine) and Rexulti (brexpiprazole) in the USA, there is a gradual uptick in new patient starts as the pandemic wanes, further supporting positive growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK